Mathematical models of rate control for communication networks

by Tan, David Kim Hong
Published 1999

Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service.

by Henrique A Parsons, Vickie E Baracos, Navjot Dhillon, David S Hong, Razelle Kurzrock
Published 2012-01-01

TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma

by Matthew J. Reilley, Brittany Morrow, Casey R. Ager, Arthur Liu, David S. Hong, Michael A. Curran
Published 2019-11-01

Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab

by Siqing Fu, Sang T. Kim, Jean Tayar, David S. Hong, Elliot Norry, Amy Sun, Danxia Ke, Juli Miller
Published 2021-07-01

Molecular Imaging with 3′-deoxy-3′[(18)F]-Fluorothymidine (¹⁸F-FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A Pilot Study

by Kalevi Kairemo, Elmer B. Santos, Homer A. Macapinlac, Shreyaskumar Patel, Anthony P. Conley, David S. Hong, Vivek Subbiah
Published 2020-02-01

Student Preferences on Gaming Aspects for a Serious Game in Pharmacy Practice Education: A Cross-Sectional Study

by Chang, Huan Ying, Poh, David Yan Hong, Wong, Li Lian, Yap, John Yin Gwee, Yap, Kevin Yi-Lwern
Published 2015-05-01

The robust and rapid role of molecular testing in precision fungal diagnostics: A case report

by Julie M. Steinbrink, David K. Hong, Stephen P. Bergin, Rami N. Al-Rohil, John R. Perfect, Eileen K. Maziarz
Published 2020-03-01

Rapid detection of invasive Mycobacterium chimaera disease via a novel plasma-based next-generation sequencing test

by Jim Nomura, Gunter Rieg, Gary Bluestone, Townson Tsai, Andrew Lai, Dawn Terashita, Sivan Bercovici, David K. Hong, Brian P. Lee
Published 2019-05-01

Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose

by Wenyuan Xiong, Manja Friese‐Hamim, Andreas Johne, Christopher Stroh, Manfred Klevesath, Gerald S. Falchook, David S. Hong, Pascal Girard, Samer El Bawab
Published 2021-05-01

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.

by Filip Janku, J Jack Lee, Apostolia M Tsimberidou, David S Hong, Aung Naing, Gerald S Falchook, Siqing Fu, Rajyalakshmi Luthra, Ignacio Garrido-Laguna, Razelle Kurzrock
Published 2011-01-01

KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.

by Ignacio Garrido-Laguna, David S Hong, Filip Janku, Ly M Nguyen, Gerald S Falchook, Siqing Fu, Jenifer J Wheler, Rajyalakshmi Luthra, Aung Naing, Xuemei Wang, Razelle Kurzrock
Published 2012-01-01

Molecular characterization of breast cancer CTCs associated with brain metastasis

by Debasish Boral, Monika Vishnoi, Haowen N. Liu, Wei Yin, Marc L. Sprouse, Antonio Scamardo, David S. Hong, Tuan Z. Tan, Jean P. Thiery, Jenny C. Chang, Dario Marchetti
Published 2017-08-01

Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials

by Roman Groisberg, David S. Hong, Amini Behrang, Kenneth Hess, Filip Janku, Sarina Piha-Paul, Aung Naing, Siqing Fu, Robert Benjamin, Shreyaskumar Patel, Neeta Somaiah, Anthony Conley, Funda Meric-Bernstam, Vivek Subbiah
Published 2017-12-01

Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine

by Apostolia-Maria Tsimberidou, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Filip Janku, Aung Naing, Siqing Fu, Sarina Piha-Paul, Carrie Cartwright, Russell R. Broaddus, Graciela M. Nogueras Gonzalez, Patrick Hwu, Razelle Kurzrock
Published 2019-12-01

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial

by Vivek Subbiah, Ecaterina Ileana Dumbrava, Yunfang Jiang, Kyaw Z. Thein, Aung Naing, David S. Hong, Siqing Fu, Sarina A. Piha-Paul, Apostolia M. Tsimberidou, Filip Janku, Funda Meric-Bernstam, Razelle Kurzrock, Gerald Falchook
Published 2020-04-01

FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.

by Denis L Jardim, Jennifer J Wheler, Kenneth Hess, Apostolia M Tsimberidou, Ralph Zinner, Filip Janku, Vivek Subbiah, Aung Naing, Sarina A Piha-Paul, Shannon N Westin, Sinchita Roy-Chowdhuri, Funda Meric-Bernstam, David S Hong
Published 2014-01-01

Associations between the gut microbiome and fatigue in cancer patients

by Joud Hajjar, Tito Mendoza, Liangliang Zhang, Siqing Fu, Sarina A. Piha-Paul, David S. Hong, Filip Janku, Daniel D. Karp, Alexej Ballhausen, Jing Gong, Abdulrazzak Zarifa, Christine B. Peterson, Funda Meric-Bernstam, Robert Jenq, Aung Naing
Published 2021-03-01

First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers

by Xingfeng Bao, Andrea Varga, David S Hong, Aparna Parikh, Geoffrey I Shapiro, Özlem Ataman, Larisa Reyderman, Terri A Binder, Min Ren, Mingjie Liu, Satish Dayal, Amy Y Siu, Pallavi Sachdev, Lucy Xu, Vijay Bhagawati-Prasad, Ilian Tchakov, Chean Eng Ooi
Published 2020-06-01

Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis

by Antoine Italiano, Shivani Nanda, Andrew Briggs, Jesus Garcia-Foncillas, Ulrik Lassen, Gilles Vassal, Shivaani Kummar, Cornelis M. van Tilburg, David S. Hong, Theodore W. Laetsch, Karen Keating, John A. Reeves, Marc Fellous, Barrett H. Childs, Alexander Drilon, David M. Hyman
Published 2020-11-01

Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors

by Filip Janku, David S. Hong, Siqing Fu, Sarina A. Piha-Paul, Aung Naing, Gerald S. Falchook, Apostolia M. Tsimberidou, Vanda M. Stepanek, Stacy L. Moulder, J. Jack Lee, Rajyalakshmi Luthra, Ralph G. Zinner, Russell R. Broaddus, Jennifer J. Wheler, Razelle Kurzrock
Published 2014-01-01